Kezar Life Sciences Inc (KZR)
$0.79
Live
Insights on Kezar Life Sciences Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 117.0%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 326.6%
Performance
- $0.77$0.81$0.79
2.15%
Downside
Day's Volatility :3.98%
Upside
1.86%
- $0.67$3.13$0.79
14.61%
Downside
52 Weeks Volatility :78.45%
Upside
74.76%
Returns
| Period | Kezar Life Sciences Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -2.38% | 1.7% | 0.0% |
6 Months | -6.3% | 11.3% | 0.0% |
1 Year | -67.29% | 5.4% | 1.3% |
3 Years | -86.06% | 13.9% | -22.1% |
Highlights
Market Capitalization | 60.1M |
Book Value | $2.58 |
Earnings Per Share (EPS) | -1.4 |
Wall Street Target Price | 11.67 |
Profit Margin | 0.0% |
Operating Margin TTM | -1503.39% |
Return On Assets TTM | -25.26% |
Return On Equity TTM | -44.54% |
Revenue TTM | 7.0M |
Revenue Per Share TTM | 0.1 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -104.2M |
Diluted Eps TTM | -1.4 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.35 |
EPS Estimate Next Year | -1.25 |
EPS Estimate Current Quarter | -0.38 |
EPS Estimate Next Quarter | -0.3 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 1377.22%
Technicals Summary
Sell
Neutral
Buy
Kezar Life Sciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Kezar Life Sciences Inc | -12.42% | -6.3% | -67.29% | -86.06% | -95.91% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Kezar Life Sciences Inc | NA | NA | NA | -1.35 | -0.45 | -0.25 | NA | 2.58 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Kezar Life Sciences Inc | Buy | $60.1M | -95.91% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Suvretta Capital Management, LLC
9.85%Avidity Partners Management LP
6.90%BlackRock Inc
6.62%Prosight Management, LP
4.62%Vanguard Group Inc
4.21%Millennium Management LLC
4.02%
Corporate Announcements
Kezar Life Sciences Inc Earnings
Kezar Life Sciences Inc’s price-to-earnings ratio stands at None
Read More
Company Information
kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
Organization | Kezar Life Sciences Inc |
Employees | 58 |
CEO | Dr. Christopher J. Kirk Ph.D. |
Industry | Health Technology |
